Shih-Shin Liang

Dr. Shih-Shin Liang

orcid

Research Focus & Metrics

Academic Career Length

23Years (2004-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 May 2006 in Journal of Chromatography A
Verified
Journal Article
Closed access
SLShih-Shin Liang
Shih-Shin Liang
HMHonest Makamba
Honest Makamba
SHShang-Yu Huang
Shang-Yu Huang
SCShu-Hui Chen
Shu-Hui Chen

1 March 2016 in NeuroToxicology
Verified
Journal Article
Closed access
YYYi-Chun Yeh
Yi-Chun Yeh
MHMei-Feng Huang
Mei-Feng Huang
SLShih-Shin Liang
Shih-Shin Liang
SHShang-Jyh Hwang
Shang-Jyh Hwang
JTJer-Chia Tsai
Jer-Chia Tsai
CCCheng-Sheng Chen
Cheng-Sheng Chen

1 August 2010 in Tetrahedron
Verified
Journal Article
Closed access
JCJui-Cheng Chang
Jui-Cheng Chang
WHWen-Yueh Ho
Wen-Yueh Ho
ISI.-Wen Sun
I.-Wen Sun
YTYung-Liang Tung
Yung-Liang Tung
MTMeng-Chin Tsui
Meng-Chin Tsui
SLShih-Shin Liang
Shih-Shin Liang

11 January 2016 in Scientific Reports
Verified
Journal Article
Open access
PDF file
THTsung-Hua Hsieh
Tsung-Hua Hsieh
CHChiaYi Hsu
ChiaYi Hsu
CTCheng-Fang Tsai
Cheng-Fang Tsai
CCChien-Chih Chiu
Chien-Chih Chiu
SLShih-Shin Liang
Shih-Shin Liang
ETEing Mei Tsai
Eing Mei Tsai
The inhibition of β-catenin/LEF-1 signaling is an emerging strategy in cancer therapy. However, clinical targeted treatment of the β-catenin/LEF-1 complex remains relatively ineffective. Therefore, development of specific molecular targets is a key approach for identifying new cancer therapeutics. Thus, we attempted to synthesize a peptide (TAT-NLS-BLBD-6) that could interfere with the interaction of β-catenin and LEF-1 at nuclei in human breast cancer cells. TAT-NLS-BLBD-6 directly interacted with β-catenin and inhibited breast cancer cell growth, invasion, migration, and colony formation as well as increased arrest of sub-G1 phase and apoptosis; it also suppressed breast tumor growth in nude mouse and zebrafish xenotransplantation models, showed no signs of toxicity, and did not affect body weight. Furthermore, the human global gene expression profiles and Ingenuity Pathway Analysis software showed that the TAT-NLS-BLBD-6 downstream target genes were associated with the HER-2 and IL-9 signaling pathways. TAT-NLS-BLBD-6 commonly down-regulated 27 candidate genes in MCF-7 and MDA-MB-231 cells, which are concurrent with Wnt downstream target genes in human breast cancer. Our study suggests that TAT-NLS-BLBD-6 is a promising drug candidate for the development of effective therapeutics specific for Wnt/β-catenin signaling inhibition.

9 January 2021 in Cells
Verified
Journal Article
Open access
PDF file
CYChih-Yu Yang
Chih-Yu Yang
TCTingwen Chen
Tingwen Chen
WLWanlun Lu
Wanlun Lu
SLShih-Shin Liang
Shih-Shin Liang
HHHsien-Da Huang
Hsien-Da Huang
DTDer-Cherng Tarng
Der-Cherng Tarng
Chronic kidney disease (CKD) has long been known to cause significant digestive tract pathology. Of note, indoxyl sulfate is a gut microbe-derived uremic toxin that accumulates in CKD patients. Nevertheless, the relationship between gut microbiota, fecal indole content, and blood indoxyl sulfate level remains unknown. In our study, we established an adenine-induced CKD rat model, which recapitulates human CKD-related gut dysbiosis. Synbiotic treatment in CKD rats showed a significant reduction in both the indole-producing bacterium Clostridium and fecal indole amount. Furthermore, gut microbiota diversity was reduced in CKD rats but was restored after synbiotic treatment. Intriguingly, in our end-stage kidney disease (ESKD) patients, the abundance of indole-producing bacteria, Bacteroides, Prevotella, and Clostridium, is similar to that of healthy controls. Consistently, the fecal indole tends to be higher in the ESKD patients, but the difference did not achieve statistical significance. However, the blood level of indoxyl sulfate was significantly higher than that of healthy controls, implicating that under an equivalent indole production rate, the impaired renal excretion contributes to the accumulation of this notorious uremic toxin. On the other hand, we did identify two short-chain fatty acid-producing bacteria, Faecalibacterium and Roseburia, were reduced in ESKD patients as compared to the healthy controls. This may contribute to gut dysbiosis. We also identified that three genera Fusobacterium, Shewanella, and Erwinia, in the ESKD patients but not in the healthy controls. Building up gut symbiosis to treat CKD is a novel concept, but once proved effective, it will provide an additional treatment strategy for CKD patients.

1 June 2015 in BBA Clinical
Verified
Journal Article
Open access
CHChun-Hao Huang
Chun-Hao Huang
CKChao-Jen Kuo
Chao-Jen Kuo
SLShih-Shin Liang
Shih-Shin Liang
SCShu-Wen Chi
Shu-Wen Chi
EHEdward Hsi
Edward Hsi
SCShyh-Horng Chiou
Shyh-Horng Chiou
Hepatocellular carcinoma (HCC), the major type of liver cancer, is among the most lethal cancers owing to its aggressive nature and frequently late detection. Therefore, the possibility to identify early diagnostic markers could be of significant benefit. Urine has especially become one of the most attractive body fluids in biomarker discovery as it can be obtained non-invasively in large quantities and is stable as compared with other body fluids. To identify potential protein biomarker for early diagnosis of HCC, we explored protein expression profiles in urine from HCC patients and normal controls (n = 44) by shotgun proteomics using nano-liquid chromatography coupled tandem mass spectrometry (nanoLC–MS/MS) and stable isotope dimethyl labeling. We have systematically mapped 91 proteins with differential expressions (p < 0.05), which included 8 down-regulated microtubule proteins and 83 up-regulated proteins involved in signal and inflammation response. Further integrated proteogenomic approach composed of proteomic, genomic and transcriptomic analysis identified that S100A9 and GRN were co-amplified (p < 0.001) and co-expressed (p < 0.01) in HCC tumors and urine samples. In addition, the amplifications of S100A9 or GRN were found to be associated with poor survival in HCC patients, and their co-amplification was also prognosed worse overall survival than individual ones. Our results suggest that urinary S100A9 and GRN as potential combinatorial biomarkers can be applied to early diagnosis of hepatocellular carcinoma and highlight the utility of onco-proteogenomics for identifying protein markers that can be applied to disease-oriented translational medicine.